0 166

Cited 10 times in

Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis

Authors
 Alvise Berti  ;  Mouaz Alsawas  ;  Tabinda Jawaid  ;  Larry J Prokop  ;  Jiwon M Lee  ;  Gwang Hun Jeong  ;  Luis F Quintana  ;  Sergey Moiseev  ;  Augusto Vaglio  ;  Vladimir Tesar  ;  Duvuru Geetha  ;  Jae I L Shin  ;  Andreas Kronbichler 
Citation
 NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol.37(11) : 2190-2200, 2022-10 
Journal Title
NEPHROLOGY DIALYSIS TRANSPLANTATION
ISSN
 0931-0509 
Issue Date
2022-10
MeSH
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy OR Antibodies, Antineutrophil Cytoplasmic OR Humans OR Immunosuppressive Agents / therapeutic use OR Microscopic Polyangiitis* OR Mycophenolic Acid / therapeutic use OR Peroxidase OR Remission Induction
Keywords
ANCA-associated vasculitis ; MMF ; granulomatosis with polyangiitis ; microscopic polyangiitis ; mycophenolate mofetil
Abstract
Background: Uncertainties exist about the use of mycophenolate mofetil (MMF) in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV), particularly for remission maintenance.

Methods: Systematic review and meta-analysis of phase II and III trials assessing the use of MMF in AAV, granulomatosis with polyangiitis and microscopic polyangiitis (MPA). A comprehensive search of several databases (Medline, EMBASE, Cochrane, Web of Science, Scopus) from inception to 5 May 2020 has been conducted. Trial data were extracted to estimate odds ratios (ORs) and estimates (ES) for MMF efficacy (remission-induction and maintenance). Severe adverse effects (SAEs) were collected.

Results: From 565 articles captured, 10 met the predefined criteria, 5 phase II and 5 III trials; 4 assessed remission-induction, 3 remission maintenance and 3 both. The pooled OR for remission-induction at 6 months was 1.06 (95% confidence interval 0.74, 1.52), with no significant difference by subgroup meta-analysis of trials stratified by different study-level features (i.e. kidney disease, MPA, myeloperoxidase-ANCA positivity, newly diagnosed disease) (P > 0.05). The overall ES for remission maintenance at the end of follow-up ranged between 51% and 91% (I2 = 74.8%). Subgroup meta-analysis identified kidney involvement as a possible source of heterogeneity, yielding a significantly higher rate of sustained remission in trials enrolling only patients with kidney involvement (92%, 76-100%) versus those enrolling patients with and without kidney involvement (56%, 45-66%). Results were similar in multiple sensitivity analyses. During follow-up, the frequency of SAEs in MMF-based treatment arms was 31.8%.

Conclusions: In AAV, MMF use was significantly associated with higher sustained remission rates in trials enrolling only patients with kidney involvement. These findings might influence clinical practice.
Full Text
https://academic.oup.com/ndt/article/37/11/2190/6462928
DOI
10.1093/ndt/gfab357
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Shin, Jae Il(신재일) ORCID logo https://orcid.org/0000-0003-2326-1820
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/193288
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links